CYCLOPHOSPHAMIDE VS MELPHALAN IN TREATMENT OF PLASMA CELL MYELOMA

被引:61
作者
RIVER, SL
PATNO, ME
机构
来源
JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1969年 / 207卷 / 07期
关键词
D O I
10.1001/jama.207.7.1328
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:1328 / &
相关论文
共 16 条
[1]  
BERGSAGEL DE, 1962, CANCER CHEMOTH REP, V21, P87
[2]  
BROCK N, 1967, CANCER, V20, P900, DOI 10.1002/1097-0142(1967)20:5<900::AID-CNCR2820200552>3.0.CO
[3]  
2-Y
[4]   PLASMACYTIC MYELOMA - A STUDY OF RELATIONSHIP OF SURVIVAL TO VARIOUS CLINICAL MANIFESTATIONS AND ANOMALOUS PROTEIN TYPE IN 112 PATIENTS [J].
CARBONE, PP ;
KELLERHOUSE, LE ;
GEHAN, EA .
AMERICAN JOURNAL OF MEDICINE, 1967, 42 (06) :937-+
[5]  
Karnofsky DA, 1949, EVALUATION CHEMOTHER, P191
[6]  
KORST DR, 1964, JAMA-J AM MED ASSOC, V189, P758
[7]  
MacLeod CM, 1949, EVALUATION CHEMOT ED, P191
[8]   CLASSIFICATION OF MYELOMA PROTEINS, BENCE JONES PROTEINS, AND MACROGLOBULINS INTO 2 GROUPS ON BASIS OF COMMON ANTIGENIC CHARACTERS [J].
MANNIK, M ;
KUNKEL, HG .
JOURNAL OF EXPERIMENTAL MEDICINE, 1962, 116 (06) :859-&
[9]   MELPHALAN (L-PHENYLALANINE NITROGEN MUSTARD) TREATMENT IN MYELOMATOSIS - REPORT OF 46 CASES [J].
NORIN, T .
ACTA RADIOLOGICA-THERAPY PHYSICS BIOLOGY, 1966, 4 (01) :33-&
[10]  
OSGOOD EE, 1960, CANCER CHEMOTH REP, V9, P1